aTyr Pharma, Inc.ATYRNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-2.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -26.93% |
| Q3 2025 | -2.52% |
| Q2 2025 | 24.50% |
| Q1 2025 | 10.22% |
| Q4 2024 | 7.67% |
| Q3 2024 | -0.18% |
| Q2 2024 | -4.70% |
| Q1 2024 | 25.38% |
| Q4 2023 | 68.90% |
| Q3 2023 | -47.13% |
| Q2 2023 | 18.06% |
| Q1 2023 | -2.78% |
| Q4 2022 | -15.01% |
| Q3 2022 | -6.90% |
| Q2 2022 | -0.95% |
| Q1 2022 | 29.68% |
| Q4 2021 | 3.67% |
| Q3 2021 | -7.17% |
| Q2 2021 | 3.87% |
| Q1 2021 | 17.04% |
| Q4 2020 | 12.28% |
| Q3 2020 | -4.75% |
| Q2 2020 | -17.14% |
| Q1 2020 | 2.94% |
| Q4 2019 | 33.62% |
| Q3 2019 | -22.22% |
| Q2 2019 | -4.38% |
| Q1 2019 | 4.89% |
| Q4 2018 | -2.46% |
| Q3 2018 | -28.80% |
| Q2 2018 | -14.59% |
| Q1 2018 | -30.90% |
| Q4 2017 | 59.45% |
| Q3 2017 | 5.94% |
| Q2 2017 | -12.98% |
| Q1 2017 | 18.45% |
| Q4 2016 | -2.51% |
| Q3 2016 | -15.90% |
| Q2 2016 | 0.27% |
| Q1 2016 | 7.92% |